Updated NCCN Guidelines for Patients®: Chronic Myelogenous Leukemia
By Lacey Marlow, Associate Medical Writer
The NCCN Guidelines for Patients®: Chronic Myelogenous Leukemia, Version 1.2014, is now available at NCCN.org/patients.
The NCCN Guidelines for Patients®: Chronic Myelogenous Leukemia has been updated to reflect the content of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myelogenous Leukemia, Version 2.2014. This NCCN Guidelines for Patients® is a high-quality resource for patients and caregivers in the process of planning or receiving treatment. It includes NCCN's most recent treatment recommendations for each phase of chronic myelogenous leukemia.
This update includes important changes to the recommended second-line treatment options. The Tyrosine Kinase Inhibitor therapy bosutinib (Bosulif®) is now recommended for patients with resistance or intolerance to prior TKI therapy. The chemotherapy drug omacetaxine (Synribo®) is now recommended for patients with resistance or intolerance to two or more TKIs. The updated NCCN Guidelines for Patients also emphasizes the importance of quantitative reverse transcriptase polymerase chain reaction (QPCR) using the International Scale for monitoring response to TKI therapy.
The NCCN Guidelines for Patients®: Chronic Myelogenous Leukemia was developed according to plain language principles to improve health literacy. The booklet design and format includes patient-friendly elements such as descriptions of recommended tests and treatments, as well as definitions of medical terms. This resource also includes medical illustrations of anatomy, tests, and treatments that may help patients to better understand the cancer and treatment process. The NCCN Guidelines for Patients®: Chronic Myelogenous Leukemia is available free-of-charge at NCCN.org/patients.
NCCN currently offers NCCN Guidelines for Patients for the following cancer types: breast, colon, ovarian, melanoma, non-small cell lung, pancreatic, and prostate cancers, chronic myelogenous leukemia, lung cancer screening, malignant pleural mesothelioma, multiple myeloma, and caring for adolescents and young adults (AYA).
About the NCCN Guidelines for Patients
NCCN aims to provide people with cancer and the general public state-of-the-art cancer treatment information in easy-to-understand language. The NCCN Guidelines for Patients, translations of the NCCN Guidelines®, are meant to help patients with cancer talk with their physicians about the best treatment options. These guidelines do not replace the expertise and clinical judgment of the physician.
Available for free, online via NCCN.org/patients, the flip-book program allows for a user-friendly viewing of the NCCN Guidelines for Patientsin electronic format with added functionality, including an interactive table of contents and the ability to perform keyword searches, zoom, print, download, share, and add bookmarks.